Vireo Advisors Coordinating OECD Workshop to Advance Use of Adverse Outcome Pathways (AOP) for Nanomaterial Risk Assessment

Vireo Advisors Coordinating OECD Workshop to Advance Use of Adverse Outcome Pathways (AOP) for Nanomaterial Risk Assessment

Vireo Advisors is collaborating with Health Canada and two European Horizon2020 projects to coordinate two back-to-back workshops at the OECD: “Advancing Adverse Outcome Pathway (NanoAOP) Development for Nanomaterial Risk Assessment and Categorization” (NanoAOP Workshop), to be held 11 September 2019, and a stakeholder workshop organized by the EU H2020 Project Physiologically Anchored Tools for Realistic nanOmateriaL hazard aSsessment (PATROLS ), to be held 12 September 2019.

Read More

FDA releases its Plant and Animal Biotechnology Innovation Action Plan

FDA releases its Plant and Animal Biotechnology Innovation Action Plan

The Food and Drug Administration (FDA) recently released its Plant and Animal Biotechnology Innovation Action Plan, which provides an overview of FDA’s efforts to develop a comprehensive policy framework for the oversight of animal biotechnology products, including food and drug products derived from intentionally genetically altered animals and plants.

Read More